ROR1: Inactive tyrosine-protein kinase transmembrane receptor ROR1
Has very low kinase activity in vitro and is unlikely to function as a tyrosine kinase in vivo.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on ROR1, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Cirmtuzumab | Phase 3 | Merck & Co. (MSD) | Antibody | InhibitorInactive tyrosine-protein kinase transmembrane receptor ROR1 inhibitor | 1 |
| Trial | Drug | Phase | Status | Lead sponsor | First posted |
|---|---|---|---|---|---|
| Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax | Cirmtuzumab | Phase 2 | Active, not recruiting | University of California, San Diego | Aug 6, 2020 |
- Hearing loss, autosomal recessive0.45
- Diffuse large B-cell lymphoma0.36
- Cervical carcinoma0.34
- Mantle cell lymphoma0.32
- Abnormality of the skeletal system0.28
- Deafness0.28
- Thrombophilia0.26
- Fracture of pelvis0.25
- Knee fracture0.22
- Smoking initiation0.22
- Septic shock0.17
- B-cell chronic lymphocytic leukemia0.15
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4665585, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt Q01973, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets